Preferred Label : Glecaprevir/Pibrentasvir;
NCIt synonyms : Glecaprevir and Pibrentasvir; Glecaprevir-Pibrentasvir;
NCIt definition : A fixed dose combination of glecaprevir, an inhibitor of the hepatitis C virus (HCV)
NS3/4A serine protease, and pibrentasvir, an inhibitor of the HCV non-structural protein
5A (NS5A), with activity against HCV genotypes 1-6. Upon oral administration of glecaprevir/pibrentasvir,
glecaprevir inhibits the HCV NS3/4A serine protease enzyme, thereby disrupting the
cleavage of the virally encoded polyprotein into mature proteins and preventing the
formation of the viral replication complex. Pibrentasvir inhibits the activity of
the NS5A protein, leading to disruption of the viral RNA replication complex, blockage
of HCV RNA production, and inhibition of viral replication. HCV is a small, enveloped,
single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated
with the development of certain cancers.;
Drug name : Mavyret; GLE/PIB;
Molecule name : ABT-493/ABT-530;
NCI Metathesaurus CUI : CL777819;
Origin ID : C160484;
UMLS CUI : C4519575;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3224398/fr/maviret
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
glecaprevir and pibrentasvir
Glecaprevir/Pibrentasvir
glecaprevir
pibrentasvir
antiviral agents
insurance, health, reimbursement
Duration of treatment (qualifier value)
hepatitis C, chronic
glecaprevir
benzimidazoles
quinoxalines
sulfonamides
glecaprevir and pibrentasvir
drug combinations
pyrrolidines
---
